Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-cash Items (2022 - 2025)

Silence Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $4.2 million for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 46.74% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 46.74% increase, with the full-year FY2025 number at $4.2 million, down 85.53% from a year prior.
  • Non-cash Items hit $4.2 million in Q4 2025 for Silence Therapeutics, up from $4.0 million in the prior quarter.
  • Over the last five years, Non-cash Items for SLN hit a ceiling of $4.2 million in Q4 2025 and a floor of $2.2 million in Q4 2022.
  • Historically, Non-cash Items has averaged $3.3 million across 4 years, with a median of $3.4 million in 2025.
  • Biggest five-year swings in Non-cash Items: fell 4.47% in 2024 and later surged 46.74% in 2025.
  • Tracing SLN's Non-cash Items over 4 years: stood at $2.2 million in 2022, then surged by 35.56% to $3.0 million in 2023, then decreased by 4.47% to $2.9 million in 2024, then soared by 46.74% to $4.2 million in 2025.
  • Business Quant data shows Non-cash Items for SLN at $4.2 million in Q4 2025, $4.0 million in Q3 2025, and $3.7 million in Q2 2025.